Prices of Remdesivir slashed, now as cheap as Rs 899, says NPPA

With this, Remdesivir injections of potency 100mg per vial have become as cheap as Rs 899.

The move comes in line with the ongoing efforts for enhancement of availability and affordability of the key antiviral drug Remdesivir, a promising therapeutic candidate for Covid-19 due to its ability to inhibit SARS-CoV-2 in vitro.

Although being approved as an investigational drug for strict use under hospital conditions, the demand for Remdesivir injection soared manifold with surging cases amid the second wave of Covid-19 across the country.

To meet this demand, NPPA, in a letter to Cadila Healthcare, Cipla Limited, Dr Reddy's Labs, Hetero Drugs, Jubilant Pharma, Mylan Labs and Syngene International sought compliance of revised MRP with respect to Remdesivir as per the DPCO, 2013.

"Based on the Form-V furnished regarding voluntary reduction in Maximum Retail Price (MRP) of Remdesivir, manufacturers/marketers of Remdesivir are hereby directed to implement the revised MRP throughout the distribution chain w.e.f. 15.04.2021, irrespective of the batch numbers," the NPPA saying quoted by IANS.

Also Read: NPPA Directs Cipla, Sun Pharma, Others To Reduce Remdesivir MRP

Now, on the intervention of the Government, the major manufacturers and marketers of Remdesivir injection have reported a voluntary reduction in Maximum Retail Price (MRP). The revised prices of major brands of 'Remdesivir Injection 100mg/Vial are as follows:

According to the details shared by the NPPA, Cadila Healthcare has reduced the price of its REMDAC (Remdesivir 100 mg) injection to Rs 899 from Rs 2,800 earlier. Similarly, Syngene International has cut the price of its brand RemWin to Rs 2,450 from Rs 3,950 earlier.